Skip to main content
SpringerLink
Log in

Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry

  • Occasional Survey
  • Published:
European Journal of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Since the introduction of radioiodinated metaiodobenzylguanidine in 1980, considerable research has been performed, both in the chemical field and in medical sciences. However, despite the wide use of radioiodinated metaiodobenzylguanidine, knowledge about its pharmacology is still limited. This paper reviews the biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry of radioiodinated metaiodobenzylguanidine. Iodine-131 metaiodobenzylguanidine therapy is in general well tolerated, but its effectiveness needs improvement. Also whole-body dosimetry as part of treatment planning needs to be improved. Future prospects on these items are included in this review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 1994;21: 561–581.

    Google Scholar 

  2. Valdés Olmos RA, Hoefnagel CA, Van der Schoot JB. Nuclear medicine in the monitoring of organ function and the detection of injury related to cancer therapy. Eur J Nucl Med 1993;20: 515–546.

    Google Scholar 

  3. Nakajo M, Shapiro B, Copp J, Kalff V, Gross MD, Sisson JC, Beierwaltes WH. The normal and abnormal distribution of the adrenomedullary imaging agent m-[I-131]iodobenzylguanidine (I-131 MIBG) in man: evaluation by scintigraphy. Nucl Med 1983;24: 672–682.

    Google Scholar 

  4. Nakajo M, Shapiro B, Sisson JC, Swanson DP, Beierwaltes WH. Salivary gland accumulation of meta-[131I]iodobenzyl-guanidine. J Nucl Med 1984;25: 2–6.

    Google Scholar 

  5. Kline RC, Swanson DP, Wieland DM, Thrall JH, Gross MD, Pitt B, Beierwaltes WH. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med 1981;22: 129–132.

    Google Scholar 

  6. Bomanji J, Britton KE. Uterine uptake of iodine-123 metaiodobenzylguanidine during the menstrual phase of uterine cycle. Clin Nucl Med 1987;12: 601–603.

    Google Scholar 

  7. Bomanji J, Moyes J, Huneidi AHS, Solanki K, Hawkins L, Nimmon CC, Kingston JE, Britton KE. Cerebral uptake of MIBG: adrenoceptors visualized? Nucl Med Commun 1991;12: 3–13.

    Google Scholar 

  8. Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, Carey JE, Swanson DP, Copp JE, Satterlee WG, Wieland DM. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984;24: 197–206.

    Google Scholar 

  9. Lynn MD, Shapiro B, Sisson JC, Swanson DP, Mangner TJ, Wieland DM, Meyers LJ, Glowniak JV, Beierwaltes WH. Portrayal of pheochromocytoma and normal human adrenal medulla by m-[123I]iodobenzylguanidine: concise communication. J Nucl Med 1984;25:436–440.

    Google Scholar 

  10. Horne T, Hawkins LA, Britton KE, Granowska M, Bouloux P, Besser GM. Imaging of phaeochromocytoma and adrenal medulla with 123I-metaiodobenzylguanidine. Nucl Med Commun 1984;5: 763–768.

    Google Scholar 

  11. Nakajo M, Shimabukuro K, Miyaji N, Shimada J, Shirono K, Sakata H, Yoshimura H, Yonekura R, Shinohara S. Rapid clearance of iodine-131 MIBG from the heart and liver of patients with adrenergic dysfunction and pheochromocytoma. J Nucl Med 1985;26: 357–365.

    Google Scholar 

  12. Sinclair AJ, Bomanji J, Harris P, Ross G, Besser GM, Britton KE. Pre- and post-treatment distribution pattern of 123I-MIBG in patients with phaeochromocytomas and paragangliomas. Nucl Med Commun 1989;10: 567–576.

    Google Scholar 

  13. Nakajo M, Shapiro B, Glowniak J, Sisson JC, Beierwaltes WH. Inverse relationship between cardiac accumulation of meta-[131I]iodobenzylguanidine (I-131 MIBG) and circulating catecholamines in suspected pheochromocytoma. J Nucl Med 1983;24: 1127–1134.

    Google Scholar 

  14. Hoefnagel CA, Voûte PA, de Kraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987;28: 308–314.

    Google Scholar 

  15. Bomanji J, Levison DA, Flatman WD, Horne T, Bouloux PMG, Ross G, Britton KE, Besser GM. Uptake of iodine-123 MIBG by pheochromocytomas, paragangliomas, and neuroblastomas: a histopathological comparison. J Nucl Med 1987;28: 973–978.

    Google Scholar 

  16. Moyes JSE, Babich JW, Carter R, Meller ST, Agrawal M, McElwain TJ. Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumor histopathology. J Nucl Med 1989;30: 474–480.

    Google Scholar 

  17. Miceli A, Nespoli L, Aprils C, Burgio GR. VMA-negative, MIBG scan-positive neuroblastoma in children. Eur J Pediatr 1986;145:325.

    Google Scholar 

  18. Jaques S Jr, Tobes MC, Sisson JC, Baker JA, Wieland DM. Comparison of the sodium dependency of uptake of meta-iodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol 1984;26: 539–546.

    Google Scholar 

  19. Tobes MC, Jaques S Jr, Wieland DM, Sisson JC. Effect of uptake-one inhibitors on the uptake of norepinephrine and metaiodobenzylguanidine. J Nucl Med 1985;26: 897–907.

    Google Scholar 

  20. Gasnier B, Roisin MP, Scherman D, Coornaert S, Desplanches G, Henry JP. Uptake of meta-iodobenzylguanidine by bovine chromaffm granule membranes. Mol Pharmacol 1986;29: 275–280.

    Google Scholar 

  21. Jaques S Jr, Tobes MC, Sisson JC. Sodium dependency of uptake of norepinephrine and m-iodobenzylguanidine into cultured human pheochromocytoma cells: evidence for uptake-one. Cancer Res 1987;47: 3920–3928.

    Google Scholar 

  22. Buck J, Bruchelt G, Girgert R, Treuner J, Niethammer D. Specific uptake of m-[125I]iodobenzylguanidine in the human neuroblastoma cell line SK-N-SH. Cancer Res 1985;45: 6366–6370.

    Google Scholar 

  23. Smets LA, Loesberg C, Janssen M, Metwally EA, Huiskamp R. Active uptake and extravesicular storage of m-iodobenzylguanidine in human neuroblastoma SK-N-SH cells. Cancer Res 1989;49: 2941–2944.

    Google Scholar 

  24. Paffenholz V, Ebener U, Kornhuber B. Uptake and release of iodine-labelled m-iodobenzylguanidine in a neuroblastoma cell culture system and its importance in neuroblastoma therapy. J Cancer Res Clin Oncol 1989;269–275.

  25. Guerreau D, Thedrez P, Fritsch P, Saccavini JC, Metivier H, Nolibe D, Masse R, Coornaert S, Chatal JF. In vitro therapeutic targeting of neuroblastomas using 125I-labelled meta-iodobenzylguanidine. Int J Cancer 1990;45: 1164–1168.

    Google Scholar 

  26. Smets LA, Janssen M, Metwally E, Loesberg C. Extragranular storage of the neuron blocking agent meta-iodobenzylguanidine (MIBG) in human neuroblastoma cells. Biochem Pharmacol 1990;39: 1959–1964.

    Google Scholar 

  27. Lashford LS, Hancock JP, Kemshead JT. Meta-iodobenzylguanidine (mIBG) uptake and storage in the human neuroblastoma cell line SK-N-BE(2C). Int J Cancer 1991;47: 105–109.

    Google Scholar 

  28. Mairs RJ, Gaze MN, Barrett A. The uptake and retention of metaiodobenzylguanidine by the neuroblastoma cell line NB1-G. Br J Cancer 1991;64: 293–295.

    Google Scholar 

  29. Montaldo PG, Lanciotti M, Casalaro A, Cornaglia-Ferraris P, Ponzoni M. Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms. Cancer Res 1991;51: 4342–4346.

    Google Scholar 

  30. Smets LA, Janssen M, Rutgers M, Ritzen K, Buitenhuis C. Pharmacokinetics and intracellular distribution of the tumor-targeted radiopharmaceutical m-iodobenzylguanidine in SKN-SH neuroblastoma and PC-12 pheochromocytoma cells. Int J Cancer 1991;48: 609–615.

    Google Scholar 

  31. Iavarone A, Lasorella A, Servidei T, Riccardi R, Mastrangelo R. Uptake and storage of m-iodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines. Cancer Res 1993;53: 304–309.

    Google Scholar 

  32. Montaldo PG, Carbone R, Ponzoni M, Cornaglia-Ferraris P. Gamma-interferon increases metaiodobenzylguanidine incorporation and retention in human neuroblastoma cells. Cancer Res 1992;52: 4960–4964.

    Google Scholar 

  33. Gaze MN, Huxham IM, Mairs RJ, Barrett A. Intracellular localization of metaiodobenzylguanidine in human neuroblastoma cells by electron spectroscopic imaging. Int J Cancer 1991;47: 875–880.

    Google Scholar 

  34. Brown RS, Sisson JC, Fisher SJ, Wahl RL. Electron microscopic autoradiographic assessment of the intracellular distribution of I-125 MIBG in human neuroblastoma xenografts. J Nucl Med 1992;33: 1021.

    Google Scholar 

  35. Clerc J, Halpern S, Fourré C, Omri F, Briançon C, Jeusset J, Fragu P. SIMS microscopy imaging of the intratumor biodistribution of metaiodobenzylguanidine in the human SK-N-SH neuroblastoma cell line xenografted in to nude mice. J Nucl Med 1993;34: 1565–1570.

    Google Scholar 

  36. Munkner T. 131I-meta-iodobenzylguanidine scintigraphy of neuroblastomas. Semin Nucl Med 1985;15: 154–160.

    Google Scholar 

  37. Feldman JM, Frankel N, Coleman RE. Platelet uptake of the pheochromocytoma-scanning agent 131I-meta-iodobenzylguanidine. Metabolism 1984;33: 397–399.

    Google Scholar 

  38. Munkner T, Joergensen L. Cellular uptake of 131I-metaiodobenzylguanidine (131I-MIBG). Eur J Nucl Med 1985;11:A22.

    Google Scholar 

  39. Guilloteau D, Chalon S, Baulieu JL, Huguet F, Desplanches G, Chambon C, Vilar MP, Pourcelot L, Besnard JC. Comparison of MIBG and monoamines uptake mechanisms: pharmacological animal and blood platelet studies. Eur J Nucl Med 1988;14:341–344.

    Google Scholar 

  40. Rutgers M, Tytgat GAM, Verwijs-Janssen M, Buitenhuis C, Voûte PA, Smets LA. Uptake of the neuron-blocking agent meta-iodobenzylguanidine and serotonin by human platelets and neuro-adrenergic tumour cells. Int J Cancer 1993;54: 290–295.

    Google Scholar 

  41. Glowniak JV, Kilty JE, Amara SG, Hoffman BJ, Turner FE. Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med 1993;34: 1140–1146.

    Google Scholar 

  42. Chan PC, Lisco E, Lisco H, Adelstein SJ. The radiotoxicity of iodine-125 in mammalian cells II. A comparative study on cell survival and cytogenetic responses to 125IUdR, 131IUdR, and 3HTdR. Radiat Res 1976;67: 332–343.

    Google Scholar 

  43. Chambon C, Baulieu JL, Guilloteau D, Valat C, Baulieu F, Itti R, Besnard JC. Cinetique de la meta(131 I) iodobenzylguanidine chez le sujet normal: analyse compartimentale. J Biophys Méd Nucl 1984;8: 198–200.

    Google Scholar 

  44. Shulkin BL, Shapiro B, Tobes MC, Shen SW, Wieland DM, Meyers LJ, Lee HT, Petry NA, Sisson JC, Beierwaltes WH. Iodine- 123–4-amino-3-iodobenzylguanidine, a new sympathoadrenal imaging agent: comparison with iodine-123 metaiodobenzylguanidine. J Nucl Med 1986;27: 1138–1142.

    Google Scholar 

  45. Clarke SEM, Lazarus CR, Edwards S, Murby B, Clarke DG, Roden TM, Fogelman I, Maisey MN. Scintigraphy and treatment of medullary carcinoma of the thyroid with iodine-131 metaiodobenzylguanidine. J Nucl Med 1987;28: 1820–1825.

    Google Scholar 

  46. Lashford LS, Moyes J, Ott R, Fielding S, Babich J, Mellors S, Gordon I, Evans K, Kemshead JT. The biodistribution and pharmacokinetics of metaiodobenzylguanidine in childhood neuroblastoma. Eur J Nucl Med 1988;13: 574–577.

    Google Scholar 

  47. Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991;18: 308–316.

    Google Scholar 

  48. Blake GM, Lewington VJ, Zivanovic MA, Ackery DM. Glomerular filtration rate and the kinetics of 123I-metaiodobenzyl-guanidine. Eur J Nucl Med 1989;15: 618–623.

    Google Scholar 

  49. Mangner TJ, Tobes MC, Wieland DM, Sisson JC, Shapiro B. Metabolism of iodine-131 metaiodobenzylguanidine in patients with metastatic pheochromocytoma. J Nucl Med 1986;27: 37–44.

    Google Scholar 

  50. Tobes MC, Fig. LM, Carey J, Geatti O, Sisson JC, Shapiro B. Alterations of iodine-131 MIBG biodistribution in an anephric patient: comparison to normal and impaired renal function. J Nucl Med 1989;30: 1476–1482.

    Google Scholar 

  51. Mangner TJ, Tobes MC, Wieland DM, Sisson JC. Metabolism of I-131-meta-iodobenzylguanidine (MIBG) in humans. J Nucl Med 1984;25:P123.

    Google Scholar 

  52. Wafelman AR, Hoefnagel CA, Beijnen JH. Renal excretion of (I-131)MIBG and metabolites in patients. Pharm Weekbl Sci 1992;14:F32.

    Google Scholar 

  53. Wafelman AR, Hoefnagel CA, Beijnen JH. HPLC determination of [I-131]MIBG and metabolites in urine of neuroblastoma patients. Pharm World Sci 1993;15:B7.

    Google Scholar 

  54. Ehninger G, Klingebiel T, Kumbier I, Schuler U, Feine U, Treuner J, Waller HD. Stability and pharmacokinetics of m-[131I]iodobenzylguanidine in patients. Cancer Res 1987;47: 6147–6149.

    Google Scholar 

  55. Schwabe D, Rohrbach E, Kohl U. Determination of m-iodobenzylguanidine in serum and urine by high-performance liquid chromatography. J Chromatogr Biomed Appl 1989;487: 177–182.

    Google Scholar 

  56. Wafelman AR, Nortier YLM, Rosing H, Underberg WJM, Maes RAA, Beijnen JH. High-performance liquid chromatographic determination of m-iodobenzylguanidine in urine of cancer patients. J Chromatogr Biomed Appl 1993;622: 71–77.

    Google Scholar 

  57. Solanki KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun 1992;13: 513–521.

    Google Scholar 

  58. Corbett RP, Peacock J, Meller ST. Inhibition of 125I metaiodobenzylguanidine (mIBG) uptake into neuroblastoma monolayers by antiemetic agents. Eur J Nucl Med 1991;18: 678.

    Google Scholar 

  59. Khafagi FA, Shapiro B, Fig. LM, Mallette S, Sisson JC. Labetalol reduces iodine-131 MIBG uptake by pheochromocytoma and normal tissues. J Nucl Med 1989;30: 481–489.

    Google Scholar 

  60. Hoefnagel CA, Schornagel J, Valdés Olmos RA. [131I]Metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J Nucl Biol Med 1991;35: 308–312.

    Google Scholar 

  61. Morais J, LeMarec H, Peltier P, Chetanneau A, Kremer M, Bardies M, Chatal JF. MIBG scintigraphy of a patient with pheochromocytoma on labetalol therapy. Clin Nucl Med 1992;308–311.

  62. Fagret D, Wolf JE, Comet M. Myocardial uptake of meta[123I]-iodobenzylguanidine ([123I]MIBG) in patients with myocardial infarct. Eur J Nucl Med 1989;15: 624–628.

    Google Scholar 

  63. Fagret D, Wolf JE, Vanzetto G, Borrel E. Myocardial uptake of metaiodobenzylguanidine in patients with left ventricular hypertrophy secondary to valvular aortic stenosis. J Nucl Med 1993;34: 57–60.

    Google Scholar 

  64. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, Glowniak JV, Sherman P, Beierwaltes WH. Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 1987;28: 1625–1636.

    Google Scholar 

  65. Blake GM, Lewington VJ, Fleming JS, Zivanovic MA, Ackery DM. Modification by nifedipine of 131I-meta-iodobenzylguanidine kinetics in malignant phaeochromocytoma. Eur J Nucl Med 1988;14: 345–348.

    Google Scholar 

  66. Smets LA, Bout B, Wisse J. Cytotoxic and antitumor effects of the norepinephrine analogue meta-iodobenzylguanidine. Cancer Chemother Pharmacol 1988;21: 9–13.

    Google Scholar 

  67. Slosman DO, Pittet N, Polla BS. In vitro comparison of cytotoxic and antiproliferative effects of cold and 131I-labeled mIBG. Eur J Nucl Med 1992;19: 607.

    Google Scholar 

  68. Hoefnagel CA, Taal BG, Valdés Olmos RA. Role of [131I]Metaiodobenzylguanidine therapy in carcinoids. J Nucl Biol Med 1991;35: 346–348.

    Google Scholar 

  69. Wheldon TE. Radionuclide therapy of cancer: particle range and therapeutic effectiveness. Nucl Med Commun 1993;14: 408–410.

    Google Scholar 

  70. Humm JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986;27: 1490–1497.

    Google Scholar 

  71. Kassis AI, Fayad F, Kinsey BM, Sastry KSR, Taube RA, Adelstein SJ. Radiotoxicity of 125I in mammalian cells. Radiat Res 1987;111: 305–318.

    Google Scholar 

  72. Wheldon TE, O'Donoghue JA, Barrett A, Michalowski AS. The curability of tumours of differing size by targeted radiotherapy using 131I or 90Y. Radiother Oncol 1991;21: 91–99.

    Google Scholar 

  73. Bruchelt G, Girgert R, Buck J, Wolburg H, Niethammer D, Treuner J. Cytotoxic effects of m-[131I- and m-[125I]iodobenzylguanidine on the human neuroblastoma cell lines SK-N-SH and SK-N-LO. Cancer Res 1988;48: 2993–2997.

    Google Scholar 

  74. Rutgers M, Gubbels AAT, Voûte PA, Hoefnagel CA, Smets LA. [131I]Metaiodobenzylguanidine (MIBG) in human neuroblastoma xenografts: tissue distribution and targetted radiotherapy. Med Pediatr Oncol 1990;18: 382.

    Google Scholar 

  75. O'Donoghue JA, Wheldon TE, Babich JW, Moyes JSE, Barrett A, Meller ST. Implications of the uptake of 131I-radiolabelled metaiodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma. Br J Radiol 1991;64: 428–434.

    Google Scholar 

  76. Gaze MN, Mairs RJ, Boyack SM, Wheldon TM, Barrett A. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes. Br J Cancer 1992;66: 1048–1052.

    Google Scholar 

  77. Senekowitsch R, Weber W, Meindl J, Bruchelt G, Kretschko J, Pabst HW. Experimental studies for therapy of neuroblastoma micrometastases with radioiodinated MIBG using multicellular tumor spheroids. J Nucl Med 1992;33: 859.

    Google Scholar 

  78. Hoefnagel CA, Lewington VJ. MIBG therapy. In: Murray IPC, Ell PJ, eds. Nuclear medicine in clinical diagnosis and treatment. London: Churchill Livingstone, in press.

  79. Vaidyanathan G, Harrison C, Welsh P, Affleck D, Zalutsky MR. In vitro cytotoxicity of m-[At-211]astatobenzylguanidine (MABG). J Nucl Med 1993;34: 218P.

  80. Rutgers M, Buitenhuis C, Voûte PA, Smets LA. High doses of unlabeled MIBG improve ‘neuroblastoma/normal tissue’ ratio of tracer [131I]MIBG in xenografted balb/c nu/nu mice. In: Evans AE, D'Angio GJ, Knudson AG, Seeger RC, eds. Advances in neuroblastoma research 4. New York: Wiley-Liss, in press.

  81. Troncone L, Rufini V, Riccardi R, Lasorella A, Mastrangelo R. The use of [131I]metaiodobenzylguanidine in the treatment of neuroblastoma after conventional therapy. J Nucl Biol Med 1991;35: 232–236.

    Google Scholar 

  82. Klingebiel T, Treuner J, Ehninger G, Keller KD, Dopfer R, Feine U, Niethammer D. 131I-Metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects. Cancer Chemother Pharmacol 1989;25: 143–148.

    Google Scholar 

  83. Matthay KK, Huberty JP, Hattner RS, Ablin AR, Engelstad BL, Zoger S, Hasegawa BH, Price D. Efficacy and safety of [131I]metaiodobenzylguanidine therapy for patients with refractory neuroblastoma. J Nucl Biol Med 1991;35: 244–247.

    Google Scholar 

  84. Koral KF, Wang X, Sisson JC, Botti J, Meyer L, Mallette S, Glazer GM, Adler RS. Calculating radiation absorbed dose for pheochromocytoma tumors in 131-I MIBG therapy. Int J Radiat Oncol Biol Phys 1989;17: 211–218.

    Google Scholar 

  85. Ott RJ, Tait D, Flower MA, Babich JW, Lambrecht RM. Treatment planning for 131I-mIBG radiotherapy of neural crest tumours using 124I-mIBG positron emission tomography. Br J Radiol 1992;65: 787–791.

    Google Scholar 

  86. Sisson JC, Hutchinson RJ, Carey JE, Shapiro B, Johnson JW, Mallette SA, Wieland DM. Toxicity from treatment of neuroblastoma with 131I-metaiodobenzylguanidine. Eur J Nucl Med 1988;14: 337–340.

    Google Scholar 

  87. Kimmig B, Bubeck B, Eisenhut M, Lange D. Die Strahlenbelastung bei der diagnostischen und therapeutischen Anwendung von 131I-meta-Benzylguanidin (MIBG). Nuc Compact 1983;14: 353–355.

    Google Scholar 

  88. Beierwaltes WH. Treatment of neuroblastoma with 131I-MIBG: dosimetric problems and perspectives. Med Pediatr Oncol 1987;15: 188–191.

    Google Scholar 

  89. Lashford LS, Lewis II, Fielding SL, Flower MA, Meller S, Kemshead JT, Ackery D. Phase I/II study of iodine 131 metaiodobenzylguanidine in chemoresistant neuroblastoma: a United Kingdom Children's Cancer Study Group investigation. J Clin Oncol 1992;10: 1889–1896.

    Google Scholar 

  90. Hoefnagel CA. Radionuclide therapy revisited. Eur J Nucl Med 1991;18: 408–431.

    Google Scholar 

  91. Fielding SL, Flower MA, Ackery DM, Kemshead J, Lashford LS, Lewis IJ. The treatment of resistant neuroblastoma with 131I-mIBG: alternative methods of dose prescription. Radiother Oncol 1992;25: 73–76.

    Google Scholar 

  92. Ertl S, Deckart H, Blottner A, Tautz M. Radiopharmacokinetics and radiation absorbed dose calculations from 131I-metaiodobenzylguanidine (131I-MIBG). Nucl Med Commun 1987;8: 643–653.

    Google Scholar 

  93. Jacobsson L, Mattsson S, Johansson L, Lindberg S, Fjälling M. Biokinetics and dosimetry of 131I-metaiodobenzylguanidine (MIBG). Proceedings Fourth International Radiopharmaceutical Dosimetry Symposium, Oak Ridge, Tennessee. 1985: 389–398.

  94. Sisson JC, Shapiro B, Hutchinson RJ, Zasadny KR, Mallette S, Mudgett EE, Wieland DM. Treatment of neuroblastoma with [125I]metaiodobenzylguanidine. J Nucl Biol Med 1991;35: 255–259.

    Google Scholar 

  95. Sisson JC, Shapiro B, Hutchinson RJ, Normole DP, Carey JE, Zasadny KR, Zempel SA. Predicting toxicity from treating neuroblastoma with 131-I MIBG and 125-I MIBG. Eur J Nucl Med 1993;20: 984.

    Google Scholar 

  96. Hoefnagel CA, Voûte PA, de Kraker J, Taal BG, den Hartog Jager FCA, Engelsman EE. Side effects of I-131-MIBG therapy of neural crest tumors. J Nucl Med 1988;29: 798–799.

    Google Scholar 

  97. Hoefnagel CA. The clinical use of 131 I-meta-iodobenzylguanidine (MIBG) for the diagnosis and treatment of neural crest tumors. Thesis, University of Amsterdam, 1989.

  98. Hutchinson RJ, Sisson JC, Shapiro B, Miser JS, Normole D, Shulkin BL, Francis IR, Zasadny K, Carey JE, Johnson JW, Mallette SA, Mudgette B. 131-I-Metaiodobenzylguanidine treatment in patients with refractory advanced neuroblastoma. Am J Clin Oncol (CCT) 1992;15: 226–232.

    Google Scholar 

  99. Voûte PA, Hoefnagel CA, de Kraker J, Evans AE, Hayes A, Green A. Radionuclide therapy of neural crest tumors. Med Pediatr Oncol 1987;15: 192–195.

    Google Scholar 

  100. Silberstein E. Incidence of adverse reactions to radiopharmaceuticals. J Nucl Med 1992;33: 1025.

    Google Scholar 

  101. Casara D, Rubello D, Saladini G, Piotto A, Pelizzo MR, Girelli ME, Busnardo B. Pregnancy after high therapeutic doses of iodine-131 in differentiated thyroid cancer: potential risks and recommendations. Eur J Nucl Med 1993;20: 192–194.

    Google Scholar 

  102. Lübke C, Martin E, Ehrenheim C, Oetting G, Fitschen J, Hundeshagen H. Assessment of the genetic risk after radioiodine therapy with regard to the gonadal dose. Eur J Nucl Med 1993;20: 893.

    Google Scholar 

  103. Dottorini ME, Mazzucchelli L, Lomuscio G, Vignati A, Colombo L. Assessment of fertility and birth histories of women treated with 131-I for differentiated thyroid carcinoma (DTC). Eur J Nucl Med 1993;20: 893.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, NL-1066 EC, Amsterdam, The Netherlands

    Amon R. Wafelman & Jos H. Beijnen

  2. Department of Nuclear Medicine, Netherlands Cancer Institute, Plesmanlaan 121, NL-1066 CX, Amsterdam, The Netherlands

    Amon R. Wafelman, Cornelis A. Hoefnagel & Jos H. Beijnen

  3. Department of Pharmaceutical Analysis and Toxicology, Faculty of Pharmacy, University of Utrecht, Sorbonnelaan 16, NL-3584 CA, Utrecht, The Netherlands

    Robert A. A. Maes

Authors
  1. Amon R. Wafelman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cornelis A. Hoefnagel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. A. Maes
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jos H. Beijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Correspondence to: A.R. Wafelman

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wafelman, A.R., Hoefnagel, C.A., Maes, R.A.A. et al. Radioiodinated metaiodobenzylguanidine: a review of its biodistribution and pharmacokinetics, drug interactions, cytotoxicity and dosimetry. Eur J Nucl Med 21, 545–559 (1994). https://doi.org/10.1007/BF00173043

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00173043

Key words

Search

Navigation